Taken together, reduced dose of Ara-C combination with moderate Aprepitant provides more effective therapeutical methods for AML treatment in vitro and in vivo with the elimination of the toxicity of Ara-C, which may pay new avenue for the usage of the routine chemotherapy drug Ara-C with low dose to enhance efficacy and reduce toxicity in clinical practice.
Keyphrases
- acute myeloid leukemia
- clinical practice
- induced apoptosis
- low dose
- oxidative stress
- chemotherapy induced
- allogeneic hematopoietic stem cell transplantation
- endoplasmic reticulum stress
- cell cycle arrest
- signaling pathway
- high dose
- locally advanced
- high intensity
- health insurance
- squamous cell carcinoma
- cell death
- cell proliferation
- radiation therapy
- drug induced
- rectal cancer
- smoking cessation